BioNTech price target lowered to $151 from $172 at Truist

Truist analyst Asthika Goonewardene lowered the firm’s price target on BioNTech (BNTX) to $151 from $172 and keeps a Buy rating on the shares. The firm notes the company’s reported Q4 revenues of EUR 1.19B were about 6% above consensus, but a bigger focus was the FY25 guidance, most notably the significantly softer revenue expectations. The silver lining, Truist believes, is that many of the potential headwinds relating to write-down may be transient. Still, given the potential risk of volatility, the firm is incrementally trimming its Comirnaty forecasts and updating OpEx to align with guidance. On the catalyst front, Truist expects 2025 to be a transformational year for BNT327, and BNT323 to lay out the pivotal data for approval.